C4U Corporation

Based in Japan, C4U Corporation specializes in innovative genome editing technology, focusing on the CRISPR-Cas3 system to facilitate advancements in medical research and agricultural enhancements. C4U Corporation, established in 2018 in Suita-shi, Japan, is engaged in genome editing technology development. The company has executed 4 deals, with the most recent funding round being a Series B amounting to JPY 1. 5 billion on May 17, 2023, led by Daiwa Corporate Investment, with participation from several other investors.

The current valuation of C4U is JPY 5,289 million. The CEO, Akimitsu Hirai, oversees operations as the company seeks to expand its reach and impact in biotechnology. C4U Corporation specializes in the development and application of innovative genome editing technology, particularly through its proprietary CRISPR-Cas3 system. This advanced technology enables precise modifications to DNA, facilitating breakthroughs in various sectors, including medical research and agricultural enhancement.

C4U's core offerings aim to address several pressing challenges, such as the development of new treatment methods for refractory diseases and the improvement of crop strains through genetic modifications. The company engages in extensive collaborations with research institutions and industry partners, enhancing the reach and applicability of its technology across diverse fields. Their products are marketed primarily in Japan, with potential expansions into other international markets as the demand for genome editing solutions grows. C4U Corporation generates revenue through a combination of strategic partnerships and research collaborations centered around its CRISPR-Cas3 technology.

The company engages in B2B transactions, providing its genome editing solutions to academic institutions, biotech firms, and agricultural companies. These transactions are structured around licensing agreements, joint research initiatives, and subscription-based models for ongoing support and access to exclusive technology updates. The revenue structure is rooted in the delivery of customized solutions and collaborative projects that leverage C4U's proprietary technology. The company's flagship offerings play a crucial role in its valuation and appeal to prospective clients within the biotechnology and agricultural sectors.

Following the Series B funding of JPY 1. 5 billion raised on May 17, 2023, C4U Corporation plans to strengthen its research and development system to enhance its business operations. The company aims to design and launch new products centered around its CRISPR technology and expand into international markets, targeting regions where demand for genome editing solutions is growing. The recent funding will facilitate these expansion initiatives, promoting innovation and collaboration across various sectors.